Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that familiar routine of calls and deadlines has predictably returned. But what can you do? After all, the world keeps spinning. On that note, we will give it a nudge by brewing another cup of stimulation. Our choice today is caramel salted mocha — a touch of the Jersey Shore. Meanwhile, here are a few items of interest to get you going. Hope your day goes well and, of course, do stay in touch. …
Emergent BioSolutions (EBS) chief executive officer Robert Kramer sold more than $10 million worth of his stock in the company in January and early February, just weeks before the disclosure that production problems at its Baltimore plant had ruined 15 million doses of the Johnson & Johnson (JNJ) Covid-19 vaccine, The Washington Post reports. Reports of the contamination came after Emergent shares had tumbled on Feb. 19, following the company’s published financial results.
May one observe that the US releasing the finished doses of the Oxford vaccine NOW to India will be of more immediate help than releasing raw materials?
Comments are closed.